1Y Close · As of Aug 26, 2026
Xcell Therapeutics operates in the Pharmaceuticals sector.
Legal name: Xcell Therapeutics Inc.
In fiscal year 2025, Xcell Therapeutics (373110) reported revenue of 1.9 billion KRW, up 0.8% from 1.9 billion KRW a year earlier.
Operating profit was -10.9 billion KRW and net income was -10.9 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 22.8 billion KRW, with a P/B of 3.19.
These figures can be verified in the DART filing (receipt no. 20260515000429).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 1.9B | -10.9B | -10.9B |
| 2024 | 1.9B | -9.3B | -9.5B |
| 2023 | 1.1B | -8.7B | -9.3B |
Recent Filings
Semi-Annual Report (2026.06)
Consolidated Operating (Preliminary) Earnings (Fair Disclosure)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Unable to determine due to missing data.
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-06 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |